Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial
To evaluate the safety and tolerability of the intravenous administration of Cx611, a preparation of allogeneic expanded adipose-derived stem cells (eASCs), in refractory rheumatoid arthritis (RA) patients, as well as to obtain preliminary clinical efficacy data in this population.
Multicentre, dose escalation, randomised, single-blind (double-blind for efficacy), placebo controlled, phase Ib/IIa clinical trial. Patients with active refractory RA...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Accepted manuscript
- Copyright holder:
- Taylor et al
- Copyright date:
- Copyright Article author (or their employer) 2016.